|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
5 human mammary carcinoma cell lines showed both amplification and overexpression of HER-2/neu.
|
1699198 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
|
16495393 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Amplification of HER-2 oncogene was analysed in DNAs obtained from 291 primary human mammary carcinomas.
|
2915900 |
1989 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
|
18086299 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
|
18086299 |
2007 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
|
25221644 |
2014 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.
|
25221644 |
2014 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
|
16091755 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
|
16091755 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
|
15994142 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
|
15994142 |
2005 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
|
20197467 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
|
20197467 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
20332317 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
|
20332317 |
2010 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
16446318 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
|
16446318 |
2006 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
|
12839951 |
2003 |